Histamindihydrochlorid-Kontrollösung Bencard Allergie (Histamine Dihydrochloride)

Histamindihydrochlorid-Kontrollösung Bencard Allergie is employed as a control agent in skin allergy testing to assess immediate‑type hypersensitivity reactions. It helps clinicians verify test reliability and compare patient responses.

• Positive control for prick and scratch tests
• Evaluation of histamine skin reactivity
• Standardization of allergen test results
• Assessment of patient’s cutaneous vascular response
• Used in research settings to study wheal‑and‑flare mechanisms

• Histamine dihydrochloride activates histamine H1 receptors on cutaneous mast cells and vascular endothelium, leading to vasodilation and increased vascular permeability. This pharmacologic action produces a localized wheal‑and‑flare response, which serves as a measurable indicator of immediate‑type hypersensitivity during skin testing.

Adverse reactions to histamine dihydrochloride solution are generally limited to the application site, but systemic effects can occur in rare cases.

Common

• Localized erythema at the test site
• Transient wheal formation lasting 15–30 minutes
• Mild itching or burning sensation
• Small amount of edema around the injection area

Serious

• Generalized urticaria
• Anaphylactic reaction (rare)
• Severe hypotension
• Bronchospasm
• Cardiovascular instability

When using Histamindihydrochlorid-Kontrollösung Bencard Allergie, clinicians should consider patient safety and test accuracy.

• Verify patient’s history of severe allergic reactions before testing
• Avoid use on compromised or infected skin
• Ensure appropriate concentration to prevent exaggerated responses
• Monitor patients for systemic reactions during and after application
• Have emergency equipment and medications readily available
• Document any unexpected reactions for future reference

Histamine dihydrochloride solution may interact with medications that influence histamine pathways or vascular tone.

Avoid

• Antihistamines (e.g., cetirizine, diphenhydramine) taken within 24 hours, which can suppress the wheal‑and‑flare response
• Systemic mast cell stabilizers that may diminish skin reactivity

Use with caution

• Beta‑blockers, which can exacerbate anaphylactic reactions
• ACE inhibitors, potentially enhancing vascular permeability
• Vasodilators that may augment local skin response
• Sedatives that could mask early signs of systemic reactions